143 related articles for article (PubMed ID: 18679414)
1. Promoter hypomethylation regulates CD133 expression in human gliomas.
Tabu K; Sasai K; Kimura T; Wang L; Aoyanagi E; Kohsaka S; Tanino M; Nishihara H; Tanaka S
Cell Res; 2008 Oct; 18(10):1037-46. PubMed ID: 18679414
[TBL] [Abstract][Full Text] [Related]
2. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.
Yi JM; Tsai HC; Glöckner SC; Lin S; Ohm JE; Easwaran H; James CD; Costello JF; Riggins G; Eberhart CG; Laterra J; Vescovi AL; Ahuja N; Herman JG; Schuebel KE; Baylin SB
Cancer Res; 2008 Oct; 68(19):8094-103. PubMed ID: 18829568
[TBL] [Abstract][Full Text] [Related]
3. Resistance to hypoxia-induced, BNIP3-mediated cell death contributes to an increase in a CD133-positive cell population in human glioblastomas in vitro.
Kahlert UD; Maciaczyk D; Dai F; Claus R; Firat E; Doostkam S; Bogiel T; Carro MS; Döbrössy M; Herold-Mende C; Niedermann G; Prinz M; Nikkhah G; Maciaczyk J
J Neuropathol Exp Neurol; 2012 Dec; 71(12):1086-99. PubMed ID: 23147506
[TBL] [Abstract][Full Text] [Related]
4. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
5. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
[TBL] [Abstract][Full Text] [Related]
7. Expression of multidrug resistance genes in normal and cancer stem cells.
Shervington A; Lu C
Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of CD133/PROM1 expression in glioma stem cells by Sp1/myc and promoter methylation.
Gopisetty G; Xu J; Sampath D; Colman H; Puduvalli VK
Oncogene; 2013 Jun; 32(26):3119-29. PubMed ID: 22945648
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.
Kagara N; Huynh KT; Kuo C; Okano H; Sim MS; Elashoff D; Chong K; Giuliano AE; Hoon DS
Am J Pathol; 2012 Jul; 181(1):257-67. PubMed ID: 22626806
[TBL] [Abstract][Full Text] [Related]
10. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.
Konduri SD; Srivenugopal KS; Yanamandra N; Dinh DH; Olivero WC; Gujrati M; Foster DC; Kisiel W; Ali-Osman F; Kondraganti S; Lakka SS; Rao JS
Oncogene; 2003 Jul; 22(29):4509-16. PubMed ID: 12881707
[TBL] [Abstract][Full Text] [Related]
11. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688
[TBL] [Abstract][Full Text] [Related]
13. Expression and regulation of AC133 and CD133 in glioblastoma.
Campos B; Zeng L; Daotrong PH; Eckstein V; Unterberg A; Mairbäurl H; Herold-Mende C
Glia; 2011 Dec; 59(12):1974-86. PubMed ID: 21901757
[TBL] [Abstract][Full Text] [Related]
14. Methylation of the prominin 1 TATA-less main promoters and tissue specificity of their transcript content.
Pleshkan VV; Vinogradova TV; Sverdlov ED
Biochim Biophys Acta; 2008 Oct; 1779(10):599-605. PubMed ID: 18602031
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation and loss of CD133 gene expression in colorectal cancers.
Jeon YK; Kim SH; Choi SH; Kim KH; Yoo BC; Ku JL; Park JG
World J Gastroenterol; 2010 Jul; 16(25):3153-60. PubMed ID: 20593500
[TBL] [Abstract][Full Text] [Related]
17. CD133 is a marker of bioenergetic stress in human glioma.
Griguer CE; Oliva CR; Gobin E; Marcorelles P; Benos DJ; Lancaster JR; Gillespie GY
PLoS One; 2008; 3(11):e3655. PubMed ID: 18985161
[TBL] [Abstract][Full Text] [Related]
18. Frequent epigenetic inactivation of the chaperone SGNE1/7B2 in human gliomas.
Waha A; Felsberg J; Hartmann W; Hammes J; von dem Knesebeck A; Endl E; Pietsch T; Waha A
Int J Cancer; 2012 Aug; 131(3):612-22. PubMed ID: 21901745
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer.
Pellacani D; Packer RJ; Frame FM; Oldridge EE; Berry PA; Labarthe MC; Stower MJ; Simms MS; Collins AT; Maitland NJ
Mol Cancer; 2011 Jul; 10():94. PubMed ID: 21801380
[TBL] [Abstract][Full Text] [Related]
20. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.
Wang J; Sakariassen PØ; Tsinkalovsky O; Immervoll H; Bøe SO; Svendsen A; Prestegarden L; Røsland G; Thorsen F; Stuhr L; Molven A; Bjerkvig R; Enger PØ
Int J Cancer; 2008 Feb; 122(4):761-8. PubMed ID: 17955491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
